Vertex Pharmaceuticals Incorporated, a prominent biotechnology company headquartered in Boston, Massachusetts, recently disclosed a change in beneficial ownership through a Form 4 filing. This filing, submitted to the Securities and Exchange Commission (SEC) on March 17, 2026, detailed a transaction involving the purchase of shares by an officer of the company. The transaction was executed under a Rule 10(b)(5)(1) trading plan, which was initiated in November 2025. As a result of this purchase, the officer’s holdings increased to approximately 35,000 shares.
Vertex Pharmaceuticals Inc., which operates within the health care sector, specializes in the discovery, development, and commercialization of pharmaceutical products aimed at treating a range of medical conditions, including cystic fibrosis, cancer, inflammatory bowel disease, autoimmune diseases, and neurological disorders. The company is committed to addressing unmet medical needs through innovative treatments and serves a global market.
The company’s stock is publicly traded on the Nasdaq stock exchange, with a close price of $451.59 as of March 17, 2026. Over the past year, Vertex Pharmaceuticals has experienced a 52-week high of $513.98 on March 23, 2025, and a 52-week low of $362.50 on August 10, 2025. The company’s market capitalization stands at approximately $114.7 billion USD, and it has a price-to-earnings ratio of 30.001.
The Form 4 filing confirms that the transaction adhered to the company’s approved trading framework and provided standard details regarding the issuer and the reporting owner. No additional corporate actions or financial developments were reported in conjunction with this filing.
Vertex Pharmaceuticals Inc. has been a publicly traded entity since its initial public offering on July 24, 1991. For more information about the company’s activities and initiatives, interested parties can visit their official website at www.vrtx.com .
